MedTrace Logo

Duration of Ameluz Application in Acral Actinic Keratoses Response

NCT03963102 · Status: TERMINATED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 28

Last updated 2024-07-26

No results posted yet for this study

Summary

A phase IV study of a single topical application of ALA for 3 hours or 4 hours to AK on acral sites (hands, feet, arms and legs), and subsequent measurement of clinical efficacy with corresponding PpIX fluorescence imaging.

Conditions

  • Actinic Keratoses
  • Photodamaged Skin

Interventions

DRUG

Ameluz

Leaving on the gel for 4 hours rather than the standard 3 hours.

Sponsors & Collaborators

  • Royal Cornwall Hospitals Trust

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-10-30
Primary Completion
2024-03-31
Completion
2024-03-31

Countries

  • United Kingdom

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03963102 on ClinicalTrials.gov